PROM1 and prostate cancer: Given the genotypic and phenotypic heterogeneity in prostate cancer, the use of single markers for the selection, identification and characterization of tumor initiating cells was elusive, and the reliability of cell surface markers, such as CD133, as a way to isolate these cells was questioned by other studies and remains controversial to date [516,517].